Kailera Therapeutics’ IPO proceeds will help world medical trials for its weight problems drug candidates. In the meantime, proteomics firm Alamar Biosciences upsized its personal IPO whereas clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue.
The put up Kailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Weight problems Medication appeared first on MedCity Information.
